Topical treatment with hexadecylphosphocholine (Miltexi®) efficiently reduces parasite burden in experimental cutaneous leishmaniasis

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 93, Issue 1, 1999, Pages 85-90

  Schmidt Ott, Ruprecht ^a,c   Klenner, Thomas ^b   Overath, Peter ^a   Aebischer, Toni ^a  

^a MAX PLANCK INST FÜR BIOLOGIE   (Germany)

^b ASTA MEDICA AG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Experimental infections; Hexadecylphosphocholine; Leishmania major; Leishmania mexicana; Mice; Topical treatment

Indexed keywords

ANTINEOPLASTIC AGENT; MILTEFOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; EXPERIMENTAL INFECTION; HEALING; HELPER CELL; HUMAN; IMMUNE RESPONSE; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; METASTASIS; MOUSE; PROMASTIGOTE; RELAPSE; SKIN LEISHMANIASIS; TOPICAL DRUG ADMINISTRATION; VISCERAL LEISHMANIASIS;

ANIMALIA; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIASIS MEXICANA; MURINAE; PROTOZOA;

EID: 0032976137     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(99)90192-X     Document Type: Article

References (42)

1. Aebischer, T., Moody, S. F. & Handman, E. (1993). Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infection and Immunity, 61, 220-226.
2. Afonso, L. C. & Scott, P. (1993). Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infection and Immunity, 61, 2952-2959.
3. Ashford, R. W., Desjeux, P. & deRaadt, P. (1992). Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitology Today, 8, 104-105.
4. Bates, P. A. & Tetley, L. (1993). Leishmania mexicana: induction of metacyclogenesis by cultivation of promastigotes at acidic pH. Experimental Parasitology, 76, 412-423.
5. Ben Salah, A., Zakraoui, H., Zaatour, A., Ftaiti, A., Zaafouri, B., Garraoui, A., Olliaro, P. L., Dellagi, K. & Ben Ismail, R. (1995). A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. American Journal of Tropical Medicine and Hygiene, 53, 162-166.
6. Berhe, N., Hailu, A. & Gemetchu, T. (1995). Human immunodeficiency virus and recurrence of cutaneous leishmaniasis long after healed localized cutaneous leishmaniasis due to Leishmania aethiopica. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89, 400-401.
7. Berman, J. D. (1997). Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clinical Infectious Diseases, 24, 684-703.
8. Biegel, D., Topper, G. & Rabinovitch, M. (1983). Leishmania mexicana: temperature sensitivity of isolated amastigotes and of amastigotes infecting macrophages in culture. Experimental Parasitology, 56, 289-297.
9. Brun, R. & Schönenberger, M. (1979). Cultivation and in vitro cloning or procyclic culture forms of Trypanosoma brucei in a semi-defined medium. Acta Tropica, 36, 289-292.
10. Burk, K., David, M., Junge, K. & Sindermann, H. (1994). Overview on the clinical development of miltefosine solution (Miltex®) for the treatment of cutaneous breast cancer. Drugs of Today, 30, (supplement B), 59-72.
11. Croft, S. L., Neal, R. A., Pendergast, W. & Chan, J. H. (1987). The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochemical Pharmacology, 36, 2633-2636.
12. Croft, S. L., Snowdon, D. & Yardley, V. (1996). The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. Journal of Antimicrobial Chemotherapy, 38, 1041-1047.
13. Delgado, O., Guevara, P., Silva, S., Belfort, E. & Ramirez, J. L. (1996). Follow-up of a human accidental infection by Leishmania (Viannia) braziliensis using conventional immunologic techniques and polymerase chain reaction. American Journal of Tropical Medicine and Hygiene, 55, 267-272.
14. Dummer, R., Krasovec, M., Roger, J., Sindermann, H. & Burg, G. (1993). Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. Journal of the American Academy of Dermatology, 29, 963-970.
15. Green, S. J., Nacy, C. A. & Meltzer, M. S. (1991). Cytokineinduced synthesis of nitrogen oxides in macrophages: a protective host response to Leishmania and other intracellular pathogens. Journal of Leukocyte Biology, 50, 93-103.
16. Grevelink, S. A. & Lerner, E. A. (1996). Leishmaniasis. Journal of the American Academy of Dermatology, 34, 257-272.
17. Guevara-Mendoza, O., Une, C., Franceschi Carreira, P. & Orn, A. (1997). Experimental infection of BALB/c mice with Leishmania panamensis and Leishmania mexicana: induction of early IFN-γ but not IL-4 is associated with the development of cutaneous lesions. Scandinavian Journal of Immunology, 46, 35-40.
18. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proceedings of the National Academy of Sciences of the USA, 88, 7011-7015.
19. Hochhuth, C. H., Vehmeyer, K., Eibl, H. & Unger, C. (1992). Hexadecylphosphocholine induces interferon-γ secretion and expression of GM-CSF mRNA in human mononuclear cells. Cellular Immunology, 141, 161-168.
20. + cells. Immunology, 87, 186-190.
21. Kaufmann-Kolle, P., Kuhlencord, A. & Eibl, H. (1996). Intravenous treatment of Leishmania donovani infected mice with liposomal hexadecylphosphocholine. Cellular and Molecular Biology Letters, 1, 429-437.
22. Klaus, S., Axelrod, O., Jonas, F. & Frankenburg, S. (1994). Changing patterns of cutaneous leishmaniasis in Israel and neighbouring territories. Transactions of the Royal Society of Tropical Medicine and Hygiene, 88, 649-650.
23. Knobloch, J. & Demar, M. (1997). Accidental Leishmania mexicana infection in an immunosuppressed laboratory technician. Tropical Medicine and International Health, 2, 1152-1155.
24. Kötting, J., Marschner, N. H., Unger, C. & Eibl, H. J. (1992). Determination of alkylphosphocholines and of alkyl- glycero-phosphocholines in biological fluids and tissues. Progress in Experimental Tumor Research, 34, 6-11.
25. Kuhlencord, A., Maniera, T., Eibl, H. & Unger, C. (1992). Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrobial Agents and Chemotherapy, 36, 1630-1634.
26. Le Fichoux, Y., Rousseau, D., Ferrua, B., Ruette, S., Lelievre, A., Grousson, D. & Kubar, J. (1998). Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrobial Agents and Chemotherapy, 42, 654-658.
27. + T-cells in experimental leishmaniasis. Infection and Immunity, 56, 2120-2124.
28. Lux, H., Hart, D. T., Parker, P. J. & Klenner, T. (1996). Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. In: Platelet-Activating Factor and Related Lipid Mediators 2, Nigam, S. (editor). New York: Plenum Press, pp. 201-211.
29. Maniera, T. (1992). Alkylphosphocholine - eine neue Substanzklasse in der Therapie der viszeralen Leishmaniose. MD Thesis, Georg-August-Universität, Göttingen, Germany.
30. + cells correlate with resolution of lesions in murine cutaneous leishmaniasis. Journal of Immunology, 149, 2715-2721.
31. Murray, H. W., Rubin, B. Y. & Rothermel, C. D. (1983). Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that IFN-γ is the activating lymphokine. Journal of Clinical Investigation, 72, 1506-1510.
32. Nabors, G. S. & Farrell, J. P. (1994). Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses. Infection and Immunity, 62, 5498-5504.
33. Nabors, G. S., Afonso, L. C., Farrell, J. P. & Scott, P. (1995). Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proceedings of the National Academy of Sciences of the USA, 92, 3142-3146.
34. Neva, F. A., Ponce, C., Ponce, E., Kreutzer, R., Modabber, F. & Olliaro, P. (1997). Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin. Transactions of the Royal Society of Tropical Medicine and Hygiene, 91, 473-475.
35. Romani, L., Puccetti, P. & Bistoni, F. (1997). Interleukin-12 in infectious diseases. Clinical Microbiology Reviews, 10, 611-636.
36. Satoskar, A., Bluethmann, H. & Alexander, J. (1995). Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infection and Immunity, 63, 4894-4899.
37. Solbach, W., Lohoff, M., Streck, H., Rohwer, P. & Röllinghoff, M. (1987). Kinetics of cell-mediated immunity, developing during the course of Leishmania major infection in "healer" and "non-healer" mice: progressive impairment of response to and generation of interleukin-2. Immunology, 62, 485-492.
38. Soto, J., Fuya, P., Herrera, R. & Berman, J. (1998). Topical paromomycin methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis - controlled study. Clinical Infectious Diseases, 26, 56-58.
39. Titus, R. G., Kelso, A. & Louis, J. A. (1984). Intracellular destruction of Leishmania tropica by macrophage activating factor/interferon. Clinical and Experimental Immunology, 55, 157-165.
40. Titus, R. G., Marchand, M., Boon, T. & Louis, J. A. (1985). A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunology, 7, 545-555.
41. Unger, C., Sindermann, H., Peukert, M., Hilgard, P., Engel, J. & Eibl, H. (1992). Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Progress in Experimental Tumor Research, 34, 153-159.
42. Warnock, R. A., Askari, S., Butcher, E. C. & von Adrian, U. H. (1998). Molecular mechanisms of lymphocyte homing to peripheral lymph nodes. Journal of Experimental Medicine, 187, 205-216.